



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 513/04 // A61K 31/425	A1	(11) International Publication Number: WO 97/03076 (43) International Publication Date: 30 January 1997 (30.01.97)
<p>(21) International Application Number: PCT/KR96/00082</p> <p>(22) International Filing Date: 1 June 1996 (01.06.96)</p> <p>(30) Priority Data: 1995/20516 12 July 1995 (12.07.95) KR</p> <p>(71) Applicant (for all designated States except US): YUNGJIN PHARMACEUTICAL CO., LTD. [KR/KR]; 277-58, Sungsu-dong 2-ka, Sungdong-ku, Seoul 133-111 (KR).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): YOO, Han, Yong [KR/KR]; 208-701, Family Apartment, 150, Moonjung-dong, Songpa-ku, Seoul 138-200 (KR). CHUNG, Kae, Jong [KR/KR]; 107-1404, Hanbo Mido Apartment, Daechi-dong, Kangnam-ku, Seoul 135-280 (KR). CHAI, Jun, Pyo [KR/KR]; 108-608, Dongsin Apartment, Jungja 1-dong, Jangnan-ku, Suwon-city, Kyunggi-do 440-301 (KR). CHANG, Man, Sik [KR/KR]; 1303-205, Mokdong Apartment, Sinjung-dong, Yangchun-ku, Seoul 158-070 (KR). KIM, Sung, Gyu [KR/KR]; 149-6, Sunhwa-3-dong, Jung-ku, Taejeon 301-053 (KR). CHOI, Wahn, Soo [KR/KR]; 144-7, Sadang-2-dong, Dongjak-ku, Seoul 152-090 (KR). KIM, Young, Hun [KR/KR]; B01, Woosong Art Villa, 869-6, Seojeong-dong, Pyungtaek-city, Kyunggi-do 459-</p>	<p>010 (KR). CHUN, Jae, Kwang [KR/KR]; 29-208, Wonpung Apartment, Gaebong-dong, Kuro-ku, Seoul 152-090 (KR). CHUNG, Young, Kuk [KR/KR]; 476-31, Ji-dong, Paldal-ku, Suwon-city, Kyunggi-do 435-040 (KR). KIM, Young, Heui [KR/KR]; 451, Sekyo-dong, Pyungtaek-city, Kyunggi-do 450-100 (KR). PAEK, Jang, Hoon [KR/KR]; 1664-16, Shilim-8-dong, Kwanak-ku, Seoul 151-018 (KR). SEO, Kwi, Hyon [KR/KR]; 392-27, Songjuk-dong, Jangnan-ku, Suwon-city, Kyunggi-do 440-210 (KR). KANG, Dae, Pil [KR/KR]; 531-3, Seojeong-dong, Pyungtaek-city, Kyunggi-do 459-010 (KR).</p> <p>(74) Agent: YOON, Dong, Yol; Yoon & Lee International Patent & Law Firm, 648-23, Yoksam-dong, Kangnam-ku, Seoul 135-081 (KR).</p> <p>(81) Designated States: CA, CN, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published With international search report.</p>	
<p>(54) Title: HETEROCYCLE-FUSED THIAZOLE DERIVATIVES</p> <p>(57) Abstract</p> <p>A thiazole compound represented by general formula (I), wherein R is hydrogen atom, a hydroxy group, a straight or branched C₁-C₆ lower alkyl group, a C₁-C₄ lower alkoxy group, phenyl group, a phenyl group having one to three substituents selected from a group consisting of a C₁-C₄ lower alkyl group, a C₁-C₄ lower alkoxy group, fluorine, chlorine, bromine and an amino group, a C₁-C₅ alkylphenyl group, a phenyl group having one to three substituents selected from a group consisting of a C₁-C₄ lower alkyl group, a C₁-C₄ lower alkoxy group, fluorine, chlorine, bromine and an amino group, a substituted or unsubstituted guanidino group, or an amino group having a general formula: NR₃R₄ in which R₃ and R₄, identical to or different from each other, represent independently a hydrogen atom, a C₁-C₆ lower alkyl group, a C₃-C₆ cycloalkyl group, a substituted or unsubstituted pyridyl group, a phenyl group having one to three substituents selected from a group consisting of a C₁-C₄ lower alkyl group, a C₁-C₄ lower alkoxy group, a halogen atom, an amino group, a cyano group and a nitro group, a piperidine group or C₁-C₄ alkylpiperidine group; R₁ and R₂, identical to or different from each other, are independently a hydrogen atom, a hydroxy group, a C₁-C₆ lower alkyl group, phenyl group, a phenyl group having one substituent selected from a group consisting of a C₁-C₄ lower alkyl group, a C₁-C₄ lower alkoxy group, a halogen atom, a nitro and a cyano group, a C₁-C₅ alkylphenyl group, or a pyridine group; R₅, R₆, R₇ and R₈, identical to or different from each other, are independently a hydrogen atom, a hydroxy group, a C₁-C₄ lower alkyl group, a C₁-C₄ lower alkoxy group, phenyl group, or a phenyl group substituted with a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group or a halogen atom, or a C₁-C₃ alkylphenyl group; Het is a 3-, 4- or 5-membered unsaturated monocyclic group, or 6- to 12-membered unsaturated fused cyclic group, said monocyclic and fused cyclic group being comprised of one or more hetero atoms selected from oxygen, oxidative nitrogen and oxidative sulfur atom are disclosed. These compounds show excellent anti-ulcer activity.</p> <div data-bbox="844 1155 1429 1491"> <p style="text-align: right;">(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

HETEROCYCLE-FUSED THIAZOLE DERIVATIVES

FIELD OF THE INVENTION

5 The present invention is related to new thiazole derivatives or their pharmaceutically acceptable salts useful as anti-ulcer agents, and to a method for producing them.

10

BACKGROUND OF THE INVENTION

It has been reported that the gastrointestinal ulcers may be caused by a excessive secretion of acids such as
15 hydrochloride acid or pepsin as well as by an action of anti-inflammatory agents such as indomethacin, toxic chemicals, pathogenic virus or toxic microorganisms. In particular, it had been reported that H^+/K^+ ATPase, an enzyme which plays an important role during the last step of the
20 acid secretion in stomach cell affects the gastric acidity (Am. J. Physiol., 1983, 245, G589, J. Biol. Chem., 1976, 251, 7690). Therefore, if a compound has an inhibitory activity against the enzyme so that it can be used to suppress gastric acid secretion and treat gastric ulcers.

25 JP 82-134417A and KR 91-7679A disclose some thiazole derivatives having anti-ulcer activity, and JP 81-5538A and USP 4,283,408 teach thiazole derivatives having an activity of suppressing the secretion of gastric juices.

However, there has been still a need to develop agents
30 which are capable of reinforcing various defensive factors

against the above described factors causing gastrointestinal ulcers.


The present inventors made extensive researches to provide novel compounds which can effectively inhibit H^+/K^+ ATPase. And a result thereof, they found out that the compounds represented by the general formula (I) given below showed not only a potent inhibitory activity against H^+/K^+ ATPase so that they can suppress the secretion of the gastric juices but also a significant cell protecting activity.

10

SUMMARY OF THE INVENTION

Therefore, an object of the present invention is to provide new thiazole derivatives represented by the following general formula (I):

20



25 wherein,

R is hydrogen atom, a hydroxy group, a straight or branched $C_1 - C_6$ lower alkyl group, a $C_1 - C_4$ lower alkoxy group, phenyl group, a phenyl group having one to three substituents selected from a group consisting of a $C_1 - C_4$ lower alkyl group, a $C_1 - C_4$ lower alkoxy group, fluorine,

30

chlorine, bromine and an amino group, a C₁ - C₅ alkylphenyl group, a phenyl group having one to three substituents selected from a group consisting of a C₁ - C₄ lower alkyl group, a C₁ - C₄ lower alkoxy group, fluorine, chlorine, bromine and an amino group, a substituted or unsubstituted guanidino group, or an amino group having a general formula : NR₃R₄ in which R₃ and R₄, identical to or different from each other, represent independently a hydrogen atom, a C₁ - C₆ lower alkyl group, a C₃ - C₆ cycloalkyl group, a substituted or unsubstituted pyridyl group, a phenyl group having one to three substituents selected from a group consisting of a C₁ - C₄ lower alkyl group, a C₁ - C₄ lower alkoxy group, a halogen atom, an amino group, a cyano group and a nitro group, a piperidine group or C₁ - C₄ alkylpiperidine group;

R₁ and R₂, identical to or different from each other, are independently a hydrogen atom, a hydroxy group, a C₁ - C₆ lower alkyl group, phenyl group, a phenyl group having one substituent selected from a group consisting of a C₁ - C₄ lower alkyl group, a C₁ - C₄ lower alkoxy group, a halogen atom, a nitro and a cyano group, a C₁ - C₅ alkylphenyl group, or a pyridine group;

R₅, R₆, R₇ and R₈, identical to or different from each other, are independently a hydrogen atom, a hydroxy group, a C₁ - C₄ lower alkyl group, a C₁ - C₄ lower alkoxy group, phenyl group, or a phenyl group substituted with a C₁ - C₄ alkyl group, a C₁ - C₄ alkoxy group or a halogen atom, or a C₁ - C₃ alkylphenyl group;

Het is a 3-, 4- or 5-membered unsaturated monocyclic group, or 6- to 12-membered unsaturated fused cyclic group, said

monocyclic and fused cyclic group being comprises of one or more hetero atoms selected from oxygen, oxidative nitrogen and oxidative sulfur atom, or their pharmaceutically acceptable salts.

5 According to the present invention, a method for producing the compounds is also provided.

The above and other objects and features of the present invention will be apparent to the skilled in the art from the following detailed description.

10

DETAILED DESCRIPTION OF THE INVENTION


Among the compounds (I) according to the present
15 invention, the compounds (I) wherein R is hydrogen atom, or methyl, ethyl, isopropyl, methoxymethyl, ethoxymethyl, methoxyethyl, aryl, phenyl, benzyl, pyridine, or guanidinyl group, or an amino group having a general formula : NR_3R_4 in which R_3 and R_4 , identical to or different from each other,
20 represent independently a hydrogen atom, or methyl, ethyl, butyl, isopropyl, aryl, cyclopropyl, cyclobutyl, cyclohexyl, phenyl, benzyl, pyridine, piperidine, or 4-methyl piperidine group; R_1 and R_2 , identical to or different from each other, are independently a hydrogen atom, a hydroxy group, or methyl,
25 ethyl, isopropyl, methoxymethyl, ethoxymethyl, methoxyethyl, aryl, phenyl, benzyl, pyridine or guanidine group; R_5 , R_6 , R_7 and R_8 , identical to or different from each other, are independently a hydrogen atom, a hydroxy group, or methyl, ethyl, isopropyl, methoxymethyl, ethoxymethyl, methoxyethyl,
30 aryl, phenyl, or benzyl group, or fluorine, chlorine or

bromine atom; and Het is a heterocyclic group such as thiazole, imidazothiazole, benzimidazothiazole, imidazopyridine or triazolothiazole group.

The pharmaceutically acceptable salts of the compound (I) of the present invention include acid-addition salts of the compound (I) with pharmaceutically acceptable organic and inorganic acids such as hydrochloric, hydrobromic, hydroiodic, phosphorous, sulfuric, nitrous, citric, formic, fumaric, maleic, tartaric, or malonic acids, an alkylsulfonic acid such as methansulfonic acid, or an arylsulfonic acid such as p-toluene sulfonic acid.

The compound represented by the general formula (I) may be prepared from the compound represented by the general formula (II) by the reactions shown in the following reaction scheme I.

[Reaction Scheme I]



Wherein, R, R₁, R₂, R₃, R₄, R₅, R₆, R₇, and R₈ have the same meanings as defined above.

5 The reaction shown in Reaction Scheme I will be described in more detail hereinafter.


 The compound (II) or its salt is dissolved into conc. aqueous solution of hydrobromic acid, and adding an equivalent halogen (particularly, bromine) while maintaining
10 the solution at a temperature of 70°C to 90°C to give a compound (III) in the form of hydrogen halogenate. The hydrogen halogenate may be neutralized with a base in an aqueous system to give the compound (III).

 The compound (III) or its salts is reacted with a
15 substituted or unsubstituted thiourea, amidinothiourea, or thioamide in a solvent to give the thiazole derivative (I) of the present invention. The examples of the solvent, which may be employed for the reaction, may include, not limited thereto, acetone, ethanol, propanol, butanol,
20 dimethylformamide, or dimethylsulfoxide and the like. The reaction may be carried out at a temperature of 50°C to 100°C. The resulting compound (I) in the form of hydrogen halogenate can be further reacted with a base in an aqueous system to give the compound (I). The compound (I) may be
25 further treated with various organic and inorganic acid to give its pharmaceutically acceptable acid addition salts. The examples of the inorganic or organic acids include those stated in the above.

 The compound (II) employed for preparing the compound
30 (I) may be prepared by the process shown in the following

Reaction Scheme II.

[Reaction Scheme II]



Wherein, R, R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈ and Het have the same meanings as defined above.

The compound (II) can be prepared by reacting a
 25 2-bromo-1,3-cyclohexadione derivative (V) with
 2-mercaptoimidazole (VIa) ("Route 1"),
 2-mercaptobenzimidazole (VIb) ("Route 2"), 3-mercaptotriazole
 (VIc) ("Route 3"), 2-aminopyridine (VI d) ("Route 4"),
 thioamide (VIe) ("Route 5") in a solvent. Alternatively, the
 30 compound (II) may be prepared by reacting the compound (X)

with thiourea compound (VIg) which is prepared by reacting the compound (V) with thiourea compound (VI f). The example of the solvent may include, not limited thereto, ethanol, propanol, butanol, acetonitrile, 1,2-dimethoxyethane. The
5 reaction is carried out at a temperature between 50°C and the boiling point of the solvent employed. The resulting compound (II) in the form of hydrobromide is neutralized with a base in an aqueous system to give the compound (II).

10 The methods and results of pharmacological experiments and acute toxicity experiments carried out using the representative compounds (I) of the present invention are described below.

1. Inhibition of H⁺/K⁺ ATPase

15 Inhibition of H⁺/K⁺ ATPase, a proton carrying enzyme, was measured by following the procedure of Saccomani *et al.* [Biochim. Biophys. Acta., 465, 311-330 (1977)]. Thus, a homogenate of the gastric mucose membrane of rabbit was used to prepare vesicles containing H⁺/K⁺ ATPase by employing
20 differential centrifugation and discontinuous density gradient centrifugation in Ficoll. The vesicles containing the enzyme were preincubated in a solution (0.5 ml) containing 1×10^{-4} M, 1×10^{-5} M, 1×10^{-6} M, or 1×10^{-7} M of the inventive compound (Example 21) and 5 mM of imidazole buffer (pH 7.4) at a
25 temperature of about 37°C for about 30 minutes. omeprazole was used as a control. A solution containing 2 mM of magnesium chloride, 40 mM of imidazole buffer (pH 7.4), 10 mM of potassium chloride and 10 mM of ATP was added to the mixture. The resulting mixture was incubated at 37°C for 15
30 minutes and the reaction was terminated by adding 1 ml of

ice-cold 22% solution of trichloroacetic acid. Enzyme activity was calculated by measuring the separated inorganic phosphate by following the method of Fiske and Subbarow [J. Biol. Chem., 66, 375-440 (1925)]. The concentrations (IC_{50}) of the test compounds which inhibit the enzyme activity by 50% are shown in Table 1.

Table 1

	Test compound	Enzyme Inhibition (IC_{50})
10	Example 1	$1.10 \times 10^{-6}M$
	Example 2	$2.16 \times 10^{-5}M$
	Example 13	$2.00 \times 10^{-4}M$
	Example 14	"
	Example 15	"
15	Example 16	"
	Example 17	$4.90 \times 10^{-5}M$
	Example 18	$1.00 \times 10^{-4}M$

2. Inhibition of Gastric Secretion

20 Inhibition of gastric secretion was measured by following the procedure of Shay ligation (Gastroenterology, 1954, 26, 903). Thus, male Sprague-Dawley rats weighing 180 - 200g were starved for 24 hours and their pylorus were ligated. Then, the inventive compounds (Examples 1, 13 and 25 17) or omeprazole as a positive control was administered into duodenum. Four hours later, the stomach was removed, and the acidity and amount of gastric juice were measured. By comparing the measured values with the acidity and amount of the gastric juice of the stomach of the reference group to 30 which no test compound was administered, the inhibition of

gastric secretion was calculated. The effective dose (ED_{50}) of the test compounds which inhibit the gastric secretion by 50% are shown in Table 2.

Table 2

5	Test Compound	Gastric juice Secretion Inhibition (ED_{50} , mg/kg)
	Example 1 Example 13 Example 17	5.08 34.0% (25 mg/kg) 15.4

10

3. Ulcer Inhibition

1) Inhibition of ethanol-induced lesions

Inhibition activity of the inventive compound on the ethanol-induced ulcer was measured by using male sprague-Dawley rats weighing 180 - 200g. Thus, rats were starved for 24 hours, and the inventive compound (Examples 1 and 17) or omeprazole as a positive control was orally administered. Thirty minutes later, absolute ethanol (5 ml/kg) was orally administered. 1.5 hours later, the stomach was removed, and the degree of the wound of the stomach was measured. By comparing the measured values with the degree of the lesion of the stomach the reference group to which no test compound was administered, the effective dose (ED_{50}) of the test compounds which inhibit the lesion by 50% were calculated and are shown in Table 3.

2) Inhibition of mepirizole-induced ulcer.

Inhibition activity of the inventive compounds on the mepirizole-induced ulcers was measured by using male Sprague-Dawley rats weighing 200 - 230g. Thus, rats were not

starved, and the inventive compounds (Examples 1 and 17) or omeprazole as a positive control was orally administered. Thirty minutes later, mepirizole suspended in 1% CMC (250 mg/kg) was orally administered. Before administration, the rats were starved, the duodena were removed. The degree of the ulcer thereof was measured. By comparing the measured values with the degree of the ulcer of the duodena of the reference group to which no test compound was administered, the effective doses (ED_{50}) of the test compounds which inhibit the ulcer by 50% were calculated and are shown in Table 3.

3) Inhibition of indomethacin-induced lesions

Inhibition activities of the inventive compounds on the indomethacin-induced lesions was measured by using male Sprague-Dawley rats. Thus, rats were starved for 48 hours and prohibited from being supplied with water for 2 hours, and 35 mg/kg of indomethacin (Sigma Co.) as a causative of gastric lesions was subcutaneously administered. Before Indomethacin treatment, the inventive compounds (Examples 1 and 17) or omeprazole as a positive control was orally administered, and the inhibitions of lesions by the action of the test compounds were observed. The effective doses (ED_{50}) of the test compounds which inhibit the lesions by 50% were measured and are shown in Table 3.

4) Inhibition of stress-induced ulcer

Inhibition activity of the inventive compound on the stress-induced ulcer was evaluated by using male Sprague-Dawley rats. Thus, rats were starved for 24 hours prior to carrying out the experiment.

Stress is an important factor for causing gastric

lesions, and was applied to rats by immersing them in water.

Thirty minutes prior to immersing rats into water, the inventive compounds (Examples 1 and 17) or omeprazole as a positive control was orally administered, and the inhibitions of ulcer by the action of the test compounds were observed. The effective doses (ED_{50}) of the test compounds which inhibit the lesions by 50% were measured and are shown in Table 3.

5) Inhibition of acetic acid-induced ulcer

Inhibition activity of the inventive compound on the acetic acid-induced ulcer was evaluated by using male Sprague-Dawley rats. Thus, rats were starved for 5 hours prior to carrying out the experiment.

20 Microliter of 30% acetic acid was injected into the submucosal layer of the stomach using a microsyringe to induce a circular ulcer on the stomach. Various doses of the inventive compounds (Examples 1 and 17) or omeprazole as a positive control were orally administered for 10 days, and the healing of ulcer by the action of the test compounds were observed. The percentages of the healing of the ulcer were calculated by comparing them with that of reference group.

Table 3

Test Compound	Anti-ulcer activity (ED_{50} , mg/kg)				
	Ethanol	Mepirizole	Indomethacin	Stress	Acetic acid*
Control (Omeprazole)	17.1	2.8	1.2	4.4	27.1
Inventive					
Ex. 1	30.8	2.6	2.95	9.2	22.67
Ex. 17	2.91	18.67	4.68	17.56	31.59

* : Percentage of healing in 30 mg/kg

4. Acute Toxicity

ICR mice (male and female) were orally administered with high doses (maximum dose : 5 g/kg) of inventive compound (Example 1) and were observed for their sudden death or a lasting of morbid conditions for 14 days. A median lethal dose (LD₅₀), an index of acute toxicity was measured and is shown in Table 4.

10

Table 4

Compound	Sexuality	Dose (mg/kg)	No. of animals	No. of Death	Lethality (%)	LD ₅₀ (mg/kg)
15 Ex. 1	Male	0	6	0	0	>5000
		40	6	0	0	
		200	6	0	0	
		1000	6	0	0	
		5000	6	0	0	
	Female	0	6	0	0	>5000
		40	6	0	0	
		200	6	0	0	
		1000	6	0	0	
		5000	6	0	0	
20						

The present invention will be described in more detail by way of Examples.

25 Example 1

Preparation of 2-amino-2,4-dihydro-8-phenylimidazo[2,1-b]benzothiazole

[Route 1]

(A) 2-Bromo-1,3-cyclohexadione

1,3-Cyclohexadione (19.6 g) was dissolved into distilled water (200 ml) at room temperature, and bromine (10.3 ml) was added dropwise at a temperature of below 5°C. The resulting precipitates were filtered, washed with cold water and dried to give the titled compound (34.9 g).

(B) 2-Phenyl-5,6-dihydroimidazo[2,1-b]benzothiazole-8(7H)-one (Compound (IIa) in Reaction Scheme II)

2-Mercapto-4-phenylimidazole (10.6 g) and 2-bromo-1,3-cyclohexadione (12.6 g) were placed into absolute ethanol (200 ml), and the reaction mixture was heated to reflux for 16 hours and then cooled to give hydrobromide salt of the desired compound (16.3 g). The hydrobromide salt was neutralized with 10% sodium carbonate solution in an aqueous system to give the titled compound (12.3 g, 76%).

m.p. : 202-203°C (240-241°C for hydrobromide)

¹H-NMR (DMSO-d₆) : δ 2.23(m, 2H), 2.62(t, 2H), 3.10(t, 2H), 7.25-7.50(m, 3H), 7.89(d, 2H), 8.49(s, 1H)

(C) 7-Bromo-2-phenyl-5,6-dihydroimidazo[2,1-b]benzothiazole-8(7H)-one hydrobromide

2-Phenyl-5,6-dihydroimidazo[2,1-b]benzothiazole-8(7H)-one hydrobromide (11.2 g) was placed into conc. hydrobromic acid (130 ml), and bromine (18.2 ml) was added dropwise to the reaction mixture while maintaining the temperature of 70 - 80°C. The reaction mixture was stirred at the same temperature for 2 hours, cooled, and washed with cold water to give yellow titled compound (12.8 g, 93%).

m.p. 214-216°C

¹H-NMR (DMSO-d₆) : δ 2.60 (m, 1H), 2.80(m, 1H), 3.15-3.75(m, 2H), 5.13(m, 1H), 7.45(m, 3H), 7.98(m, 2H), 8.59(s, 1H)

(D) 2-Amino-2,4-dihydro-8-phenylimidazo[2,1-b]benzothiazole
7-Bromo-2-phenyl-5,6-dihydroimidazo[2,1-b]benzothiazole
-8(7H)-one hydrobromide (6.22 g) and thiourea (1.22 g) were
placed into absolute ethanol (90 ml), and the reaction
5 mixture was heated to reflux for 3 hours and then cooled to
give dihydrobromide of the desired compound (5.85 g). The
dihydrobromide was neutralized with 10% potassium hydroxide
solution in an aqueous system to give pale yellow solids,
which were recrystallized with dimethylformamide (20 ml) to
10 give the titled compound (3.1 g, 66%).

m.p. : 275-276°C (248-250°C for dihydrobromide)

¹H-NMR (CDCl₃) : δ 2.95-3.28(m, 4H), 7.15(br.s, 2H),
7.18-7.46(m, 3H), 7.87(d, 2H), 8.34(s, 1H)

[Route 2]

15 (A) 2-Amino-4,5-dihydrobenzothiazole-7(6H)-one

2-Bromo-1,3-cyclohexadione (30 g) prepared in Route 1
(A) was suspended into absolute ethanol, and thiourea (13)
was added thereto. The reaction mixture was heated to
reflux for 12 - 15 hours. After completion of the reaction,
20 the reaction mixture was cooled to room temperature and
concentrated under reduced pressure to evaporate the
solvent. Acetone (70 ml) was added to the residue to give
solids, which were filtered, washed with acetone (30 ml) and
dried to give hydrobromide of the titled compound (27g,
25 71%). The hydrobromide was neutralized with sodium
hydroxide solution to give the titled compound (18g, 68%).


(B) 2-Phenyl-5,6-dihydroimidazo[2,1-b]benzothiazole-8(7H)-
one

2-Amino-4,5-dihydrobenzothiazole-7(6H)-one (18g)
30 prepared in the above (A) was dissolved into dimethylformamide

(250 ml), and 2-bromoacetophenone (21.83 g) was added thereto followed by heating to reflux for 12 - 15 hours. After completion of the reaction, the reaction mixture was cooled to room temperature and placed into distilled water. 5 The resulting precipitates were filtered, neutralized with sodium hydroxide solution, filtered, washed with ethyl acetate (100 ml), and dried to give the titled compound (21.25 g, 76%).

10 Examples 2-12

By following the procedure described in Example 1 by employing 7-bromo-2-phenyl-5,6-dihydroimidazo[2,1-b]benzothiazole-8(7H)-one hydrobromide (6.22 g) prepared in Example 1, Route 1 (D) and various thiourea derivatives for 15 various reaction times, there were obtained inventive compounds of Examples 2-12. These compounds and their physical properties are shown in Table 5.



20

25

30

Table 5

Compd.	R	Yield (%)	mp (°C) [lit (°C)]	¹ H-NMR (DMSO-d ₆) : δ
5 Ex. 2	Methyl-amino	63 69	265-267 224-227	2.85(d, 3H), 3.12(m, 4H), 7.28(d, 1H), 7.40(dd, 2H), 7.64(bs.d, 1H), 7.88(d, 2H), 7.32(s, 1H)
Ex. 3	Ethyl-amino	63 69	251-254 254-257	1.20(t, 3H), 3.15(m, 4H), 3.27(qx5, 2H), 7.29(dd, 1H), 7.42(dd, 2H), 7.72(t, 1H), 7.88(d, 2H), 8.35(s, 1H)
10 Ex. 4	Cyclo-propyl-amino	64 69	275-278 253-256	0.64(m, 2H), 0.78(m, 2H), 2.63(m, 1H), 3.18(m, 4H), 7.28(dd, 1H), 7.42(dd, 2H), 7.87(d, 2H), 8.14(s, 1H), 8.35(s, 1H)
Ex. 5	2-Methoxyethyl-amino	54 57	220-222 213-216	3.13(m, 4H), 3.31(s, 3H), 3.42(m, 2H), 3.51(m, 2H), 7.29(dd, 1H), 7.42(dd, 2H), 7.81(bs, 1H), 7.88(d, 2H), 8.35(s, 1H)
15 Ex. 6	Phenyl-amino	55 59	>300 >300	3.27(m, 4H), 7.12(dd, 1H), 7.38(dd, 1H), 7.47(m, 3H), 7.88(m, 4H), 8.05(d, 1H), 8.88(s, 1H)
Ex. 7	Benzyl-amino	66 68	258-260 235-237	3.15(m, 4H), 4.48(d, 2H), 7.21-7.48(m, 7H), 7.29(dd, 1H), 7.42(dd, 2H), 7.81(bs, 1H), 7.88(d, 2H), 8.35(s, 1H)
20 Ex. 8	Allyl-amino	59 61	234-237 230-234	3.17(m, 4H), 3.91(m, 2H), 5.21(m, 2H), 5.93(m, 1H), 7.28(dd, 1H), 7.41(dd, 2H), 7.38(d, 2H), 7.80(bs, 1H), 8.35(s, 1H)
Ex. 9	Dimethyl-amino	61 67	212-216 220-223	3.08(s, 6H), 3.19(m, 4H), 7.28(dd, 1H), 7.42(dd, 2H), 7.87(d, 2H), 8.32(s, 1H)
25 Ex. 10	-N=C(NH ₂) ₂	42 45	>300 >300	3.18(m, 4H), 6.88(bs, 4H), 7.28(dd, 1H), 7.42(dd, 2H), 7.88(d, 2H), 8.34(s, 1H)
Ex. 11	1-Pipera-zino	65 81	284-288 290-294	3.08-3.28(m, 8H), 3.49-3.66(m, 4H), 7.29(dd, 1H), 7.43(dd, 1H), 7.88(d, 2H), 8.38(s, 1H)
30 Ex. 12	3-Pyridinyl	50 51	245-248 248-252	3.38(m, 4H), 7.31(dd, 1H), 7.42(dd, 2H), 7.58(dd, 1H), 7.89(d, 2H), 8.10(d, 1H), 8.42(s, 1H), 8.70(d, 1H), 9.15(s, 1H)

Example 13

Preparation of 2-amino-4,5-dihydrobenzimidazo[2,1-b]
thiazolo[5,4-g]benzothiazole dihydrobromide

2-Bromo-1,3-cyclohexadione prepared in Example 1,
5 Route 1 (A) was reacted with 2-mercaptobenzimidazole in the
same manner as that of Example 1, Route 1 (B) to give
1,2-dihydrobenzimidazo[2,1-b]benzothiazole-4(3H)-one
(Compound (IIb) of Reaction Scheme II), which was subjected
to bromination in the same manner as that of Example 1, Route
10 1 (C) to give 3-bromo-1,2-dihydrobenzimidazo[2,1-b]
benzothiazole-4(3H)-one hydrobromide. The hydrobromide
(1.45 g) and thiourea (0.15 g) were placed into ethanol (50
ml), and the mixture was heated to reflux for 2 hours,
cooled, and the filtered to give the titled compound (61%).

15 m.p. above 300°C

¹H-NMR (DMSO-d₆) : δ 3.15(t, 2H), 3.55(t, 2H), 7.15(br.s,
1H), 7.30(m, 2H), 7.70(d, 1H), 7.98(d, 1H)

Examples 14

Preparation of 2-amidino-4,5-dihydrobenzimidazo[2,1-b]
20 thiazolo[5,4-g]benzothiazole

3-Bromo-1,2-dihydrobenzimidazo[2,1-b]benzothiazole-4(3H)
-one hydrobromide (1.0 g) prepared in Example 2 was reacted
with amidinothiourea (0.59 g) in n-butanol (40 ml) while
25 heating to reflux for 15 hours. After completion of the
reaction, the reaction mixture was cooled and filtered to give
dihydrobromide (0.65 g) of the desired compound. The
dihydrobromide was neutralized with sodium carbonate solution
in an aqueous system to give the titled compound (55%).

30 m.p. above 300°C (above 300°C for dihydrobromide)

¹H-NMR (DMSO-d₆) : δ 3.30(t, 2H), 3.60(t, 2H), 6.90(s, 4H),
7.35(m, 2H), 7.70(d, 2H), 7.97(d, 1H)

Example 15

Preparation of 2-amino-4,5-dihydro[1,2,4]triazolo[5,1-b]
5 thiazolo[5,4-g]benzothiazole

(A) 7-Bromo-5,6-dihydro[1,2,4]triazolo[5,1-b]benzothiazole
-8(7H)-one hydrobromide

2-Bromo-1,3-cyclohexadione (4.4 g) prepared in Example
1, Route 1 (A) and 1H-1,2,4-triazole-3-thiol (2.32 g) were
10 dissolved into absolute ethanol (50 ml), and the reaction
mixture was heated to reflux for 5 hours. After completion of
the reaction, the reaction mixture was cooled and filtered to
give 5,6-dihydro[1,2,4]triazolo[5,1-b]benzothiazole-8(7H)
-one hydrobromide (2.84 g, compound (IIc) of Reaction Scheme
15 II). The hydrobromide was dissolved into anhydrous acetic
acid (20 ml) and an equivalent amount of bromine was added
dropwise thereto at a temperature of 100°C, and the mixture
was stirred at the same temperature for 30 minutes. The
reaction mixture was cooled to give the titled compound
20 (95%) as solids.

¹H-NMR (DMSO-d₆) : δ 2.6(m, 2H), 2.8-2.91(m, 1H), 3.2-3.4(m,
2H), 5.15(t, 1H), 8.5(s, 1H)

(B) 2-Amino-4,5-dihydro[1,2,4]triazolo[5,1-b]thiazolo[5,4-g]
benzothiazole

25 7-Bromo-5,6-dihydro[1,2,4]triazolo[5,1-b]benzothiazole
-8(7H)-one hydrobromide (1.3 g) prepared in the above (A) and
thiourea (1.06 g) were dissolved into ethanol (50 ml), and the
solution was heated to reflux for 2 hours. After completion
of the reaction, the reaction mixture was cooled and filtered
30 to give solids (0.6 g), which are dihydrobromide of the

desired compound. The dihydrobromide was neutralized with sodium carbonate in an aqueous system to give the titled compound (60%).

m.p. above 300°C

5 ¹H-NMR (DMSO-d₆) : δ 3.1(t, 2H), 3.28(t, 2H), 7.25(br.s, NH₂),
8.31(s, 1H)

Examples 16

Preparation of 2-amidino-4,5-dihydro[1,2,4]triazolo[5,1-b]thiazolo[5,4-g]benzothiazole

10 7-Bromo-5,6-dihydro[1,2-4]triazolo[3,2-b]benzothiazole-8(7H)-one hydrobromide (1.3 g) prepared in Example 4 (A) was reacted with amidinothiourea (1.41 g) in ethanol (50 ml) while heating to reflux for 4.5 hours. After completion of the reaction, the reaction mixture was cooled and filtered to give
15 dihydrobromide (0.82 g) of the desired compound. The dihydrobromide was neutralized with sodium carbonate solution in an aqueous system to give the titled compound (73%).

m.p. above 300°C

¹H-NMR (DMSO-d₆) : δ 3.1(t, 2H), 3.25(t, 2H), 6.85(br.s, 2NH₂),
20 8.3(s, 1H)

Example 17

Preparation of 2-amino-4,5-dihydropyrido[1,2-a]thiazolo[5,4-g]benzimidazole

(A) 6,7-Dihydropyrido[1,2-a]benzimidazole-9(8H)-one

25 (Compound (IIId) of Reaction Scheme II)

2-Bromo-1,3-cyclohexadione (9.55 g) prepared in Example 1, Route 1 (A) and 2-aminopyridine (4.7 g) were dissolved into absolute ethanol (200 ml), and the reaction mixture was heated to reflux for 20 hours. After completion of the reaction,
30 the reaction mixture was concentrated under reduced pressure,

and the residue was dissolved into water. The solution was neutralized with sodium carbonate, extracted with chloroform three times, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica
5 gel column chromatography (eluant : methylene chloride : acetonitrile = 2:1) to give the titled compound (3.0 g, 32%).
¹H-NMR (DMSO-d₆) : δ 2.18(m, 2H), 2.6(m, 2H), 2.98(t, 2H),
7.25(t, 1H), 7.72(m, 2H), 9.2(d, 1H)

(B) 2-amino-4,5-dihydropyrido[1,2-a]thiazolo[5,4-g]
10 benzimidazole

6,7-Dihydropyrido[1,2-a]benzimidazole-9(8H)-one
prepared in the above (A) was subjected to bromination in the similar manner to that of Example 1, Route 1(C) to give
8-bromo-6,7-dihydropyrido[1,2-a]benzimidazole-9(8H)-one
15 hydrobromide. The resulting compound (17.4 g) and thiourea (6.0 g) were dissolved into absolute ethanol (200 ml), and the solution was heated to reflux for 4 hours. After completion of the reaction, the reaction mixture was cooled and filtered to give solids (10.6 g), which are
20 dihydrobromide of the desired compound. The dihydrobromide was neutralized with 2N-potassium hydroxide in an aqueous system and recrystallized with a mixture of DMF and ethanol to give the titled compound (7.1g, 56%).

m.p. 249°C

25 ¹H-NMR (DMSO-d₆) : δ 3.1(m, 4H), 7.28(s, NH₂), 7.50(t, 1H),
7.75(t, 1H), 7.92(d, 1H), 9.10(d, 1H)

Example 18

Preparation of 2-amidino-7-amino-4,5-dihydrobenzo
[1,2-d:3,4-d']bisthiazole

30 (A) 2-Amidino-6-bromo-4,5-dihydrobenzothiazole-7(6H)-one

2-Bromo-1,3-cyclohexadione prepared in Example 1, Route 1 (A) was reacted with amidinothiourea in the similar manner to that of Example 1, Route 1(B) to give 2-amidino-4,5-dihydrobenzothiazole-7(6H)-one hydrobromide. The hydrobromide (3.4 g) was dissolved into conc. hydrobromic acid (20 ml), and one equivalent of bromine was added dropwise at a temperature of 85°C. The mixture was stirred at a temperature of 80°C to 90°C for 30 minutes, cooled and filtered. The solids were neutralized with sodium carbonate to give the titled compound (3.17 g, 67%).

¹H-NMR (DMSO-d₆) : δ 2.0 -2.45(m, 2H), 2.5-2.85(m, 2H), 4.8(t, 2H), 7.3(br.s, 2NH₂)

(B) 2-amidino-7-amino-4,5-dihydrobenzo[1,2-d:3,4-d']bisthiazole 2-Amidino-6-bromo-4,5-dihydrobenzothiazole-7(6H)-one (1.4 g) prepared in the above (A) was reacted with thiourea (0.38 g) in ethanol while heating to reflux for 3 hours. After completion of the reaction, the reaction mixture was cooled and filtered to give hydrobromide of the desired compound (0.5 g). The hydrobromide was neutralized with sodium carbonate in an aqueous system to give the titled compound (22%).

m.p. above 300°C (above 300°C for hydrobromide)


¹H-NMR (DMSO-d₆) : δ 2.85(m, 4H), 6.9(br.s, NH₂), 7.6(br.s, 2NH₂)

25

It is understood that the foregoing detailed description is given merely by way of illustration and that modifications and variations may be made therein without departing from the spirit and scope of the invention.

CLAIMS

1. A compound represented by the following general formula (I):



wherein,

R is hydrogen atom, a hydroxy group, a straight or branched C₁ - C₆ lower alkyl group, a C₁ - C₄ lower alkoxy group, phenyl group, a phenyl group having one to three substituents selected from a group consisting of a C₁ - C₄ lower alkyl group, a C₁ - C₄ lower alkoxy group, fluorine, chlorine, bromine and an amino group, a C₁ - C₅ alkylphenyl group, a phenyl group having one to three substituents selected from a group consisting of a C₁ - C₄ lower alkyl group, a C₁ - C₄ lower alkoxy group, fluorine, chlorine, bromine and an amino group, a substituted or unsubstituted guanidino group, or an amino group having a general formula : NR₃R₄ in which R₃ and R₄, identical to or different from each other, represent independently a hydrogen atom, a C₁ - C₆ lower alkyl group, a C₃ - C₆ cycloalkyl group, a substituted or unsubstituted pyridyl group, a phenyl group having one to three substituents selected from a group consisting of a C₁ - C₄ lower alkyl group, a C₁ - C₄ lower alkoxy group, a halogen atom, an amino group, a cyano group and a nitro group, a piperidine group or C₁ - C₄

15

20

25

30

alkylpiperidine group;

R₁ and R₂, identical to or different from each other, are independently a hydrogen atom, a hydroxy group, a C₁ - C₆ lower alkyl group, phenyl group, a phenyl group having one substituent selected from a group consisting of a C₁ - C₄ lower alkyl group, a C₁ - C₄ lower alkoxy group, a halogen atom, a nitro and a cyano group, a C₁ - C₅ alkylphenyl group, or a pyridine group;

R₅, R₆, R₇ and R₈, identical to or different from each other, are independently a hydrogen atom, a hydroxy group, a C₁ - C₄ lower alkyl group, a C₁ - C₄ lower alkoxy group, phenyl group, or a phenyl group substituted with a C₁ - C₄ alkyl group, a C₁ - C₄ alkoxy group or a halogen atom, or a C₁ - C₃ alkylphenyl group;

Het is a 3-, 4- or 5-membered unsaturated monocyclic group, or 6- to 12-membered unsaturated fused cyclic group, said monocyclic and fused cyclic group being comprises of one or more hetero atoms selected from oxygen, oxidative nitrogen and oxidative sulfur atom, or its pharmaceutically acceptable salts.

2. The compound (I) according to claim 1, wherein

R is hydrogen atom, or methyl, ethyl, isopropyl, methoxymethyl, ethoxymethyl, methoxyethyl, aryl, phenyl, benzyl, pyridine, or guanidinyll group, or an amino group having a general formula : NR₃R₄ in which R₃ and R₄, identical to or different from each other, represent independently a hydrogen atom, or methyl, ethyl, butyl, isopropyl, aryl, cyclopropyl, cyclobutyl, cyclohexyl, phenyl, benzyl, pyridine, piperidine, or 4-methyl piperidine group;

R_1 and R_2 , identical to or different from each other, are independently a hydrogen atom, a hydroxy group, or methyl, ethyl, isopropyl, methoxymethyl, ethoxymethyl, methoxyethyl, aryl, phenyl, benzyl, pyridine or guanidine
5 group;

R_5 , R_6 , R_7 and R_8 , identical to or different from each other, are independently a hydrogen atom, a hydroxy group, or methyl, ethyl, isopropyl, methoxymethyl, ethoxymethyl, methoxyethyl, aryl, phenyl, or benzyl group, or fluorine,
10 chlorine or bromine atom; and

Het is a heterocyclic group such as thiazole, imidazothiazole, benzimidazothiazole, imidazopyridine or triazolothiazole group,
or its pharmaceutically acceptable salts.

15

3. The compound (I) according to claim 1, wherein

R is hydrogen atom, or methyl, ethyl, isopropyl, aryl, phenyl, benzyl, or guanidinyl group, or an amino group having a general formula : NR_3R_4 in which R_3 and R_4 , identical
20 to or different from each other, represent independently a hydrogen atom, or methyl, ethyl, butyl, isopropyl, aryl, cyclopropyl, cyclohexyl, phenyl, benzyl, pyridine, piperidine, or 4-methyl piperidine group; and


Het is thiazole, imidazothiazole, benzimidazothiazole,
25 imidazopyridine or triazolothiazole group,
or its pharmaceutically acceptable salts.

4. The compound (I) according to claim 1, which is 2-amino-4,5-dihydro-8-phenylimidazo[2,1-b]thiazolo[5,4-g]
30 benzothiazole, or its pharmaceutically acceptable salts.

5. The compound (I) according to claim 1, which is 2-amino-4,5-dihydropyrido[1,2-a]thiazolo[5,4-g]benzimidazole, or its acceptable salts.

5

6. A process for producing a compound represented by the following general formula (I):



wherein

15 R is hydrogen atom, or methyl, ethyl, isopropyl, methoxymethyl, ethoxymethyl, methoxyethyl, aryl, phenyl, benzyl, pyridine, or guanidinyll group, or an amino group having a general formula : NR_3R_4 in which R_3 and R_4 , identical to or different from each other, represent independently a
20 hydrogen atom, or methyl, ethyl, butyl, isopropyl, aryl, cyclopropyl, cyclobutyl, cyclohexyl, phenyl, benzyl, pyridine, piperidine, or 4-methyl piperidine group;


R_1 and R_2 , identical to or different from each other, are independently a hydrogen atom, a hydroxy group, or methyl,
25 ethyl, isopropyl, methoxymethyl, ethoxymethyl, methoxyethyl, aryl, phenyl, benzyl, pyridine or guanidine group;

R_5 , R_6 , R_7 and R_8 , identical to or different from each other, are independently a hydrogen atom, a hydroxy group, or methyl, ethyl, isopropyl, methoxymethyl, ethoxymethyl,
30 methoxyethyl, aryl, phenyl, or benzyl group, or fluorine,


chlorine or bromine atom; and

Het is a heterocyclic group such as thiazole, imidazothiazole, benzimidazothiazole, imidazopyridine or triazolothiazole group,

5 or its pharmaceutically acceptable salts, which comprises a step of subjecting a compound represented by a general formula (II)




wherein, R_1 , R_2 , R_5 , R_6 , R_7 , R_8 and Het have the same meanings
15 as defined above, or its salts to bromination to give a compound represented by a general formula (III)



25 wherein, R_1 , R_2 , R_5 , R_6 , R_7 , R_8 and Het have the same meanings as defined above,

reacting the compound (III) or its salts with a compound represented by a following general formula (IV),



wherein R has the same meanings as defined above,
5 to give the compound (I) or its pharmaceutically acceptable
salts.

10

15

20

25

30

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 96/00082

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: C 07 D 513/04 // A 61 K 31/425

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: C 07 D 513/00 // A 61 K 31/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

AT

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DARC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Chem. abstr., Vol. 83, No. 15, 13 October 1975 (Columbus, Ohio, USA), page 503, column 2, abstract No. 131540n, REMERS W.A. et al. "Tricyclic heterocycles derived from 4-oxo-4,5,6,7-tetrahydrobenzo[b]furan", J. Heterocycl. Chem. 1975, 12(2), 421-2. -----	1,6

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

05 September 1996 (05.09.96)

Date of mailing of the international search report

18 September 1996 (18.09.96)

Name and mailing address of the ISA/ AT

AUSTRIAN PATENT OFFICE

Kohlmarkt 8-10

A-1014 Vienna

Facsimile No. 1/53424/535

Authorized officer

Brus

Telephone No.

1/5337058/32